about
Hair diseases: a big problem on a small surfaceTNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.Seborrhoeic dermatitis and a herpes zoster infection developed during treatment with adalimumab due to Crohn's diseaseMadelung's disease in a patient with chronic renal insufficiency: a case report and review of literatureExtensive phlegmon and pyoderma gangrenosum: diagnostic difficultiesNew aspects of the treatment of alopecia areataPhysiochemical properties and application of hyaluronic acid: a systematic review.Primary Locations of Malignant Melanoma Lesions Depending on Patients’ Gender and AgeNewer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.Body mass index and body surface area in scleroderma patients.Overweight and obesity may play a role in the pathogenesis of chronic spontaneous urticaria.Influence of Adalimumab on the Expression Profile of Genes Associated with the Histaminergic System in the Skin Fibroblasts In Vitro.Pregnancy: a therapeutic dilemma.Psoriasis Treatment Changes the Expression Profile of Selected Caspases and their Regulatory MicroRNAsClinical and molecular evaluation of therapy with the use of cyclosporine A in patients with psoriasis vulgarisEffect of adalimumab on the expression of genes encoding TNF-α signal paths in skin fibroblastsThe impact of diabetes and metabolic syndromes to the effectiveness of cyclosporine a pharmacotherapy in psoriatic patients.The analysis of the therapeutic potential of ustekinumab in psoriasis vulgaris treatment.Are new variants of psoriasis therapy (IL-17 inhibitors) safe?Adalimumab changes the expression profile of selected BCL-2 family genesmRNA level of ROCK1, RHOA, and LIMK2 as genes associated with apoptosis in evaluation of effectiveness of adalimumab treatmentAnalysis of the clinical response and changes in the expression of TNF-α and its TNFR1 and TNFR2 receptors in patients with psoriasis vulgaris treated with ustekinumabChanges in the Expression Profile of JAK/STAT Signaling Pathway Genes and Mirnas Regulating their Expression Under the Adalimumab TherapyAssessment of transcriptional activity genes associated with the IL-17 signaling pathway in skin fibroblasts under the influence of adalimumabBMI changes and concentration of selected morphological and biochemical indices during cyclosporin A therapyEvaluation of expression pattern of selected genes associated with IL12/23 signaling paths in psoriatic patients during cyclosporine A therapyThe correlation between serum E-selectin levels and soluble interleukin-2 receptors with relation to disease activity in localized sclerodermaEvaluation of changes in expression pattern of oxidative stress genes under the influence of adalimumabThe Capability to Forecast Response to Therapy with Regard to The Time and Intensity of The Inflammatory Process in vitro in Dermal Fibroblasts Induced by IL-12Values of body mass index (BMI) and body surface area (BSA) in patients with psoriatic arthritis treated with adalimumab: Preliminary reportThe influence of adalimumab on the expression profile of mRNAs and miRNAs related to the IL-12 and IL-23 signal pathsThe influence of ustekinumab on expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in patients with psoriasis and in a controlVariances in the mRNA expression profile of TGF-β1-3 isoforms and its TGF-βRI-III receptors during cyclosporin a treatment of psoriatic patientsA case of ingrown nail using buckle VHO-Osthold® Perfect as a method of conservative treatment
P50
Q28073835-C09C66CF-1254-44EC-8D1F-6C295E862896Q30383054-3B9C4D7B-0734-4BA2-B088-02711AA4FE03Q30403087-F11C8A3D-B262-4F5B-9CE5-7FDDF934F6B0Q33955602-0F5D6CDD-3986-4C39-80EE-05066EAC024CQ35178531-5EF84B3B-2BD6-4811-B212-A5B9F9A8B013Q38254128-F9C7933B-8C9A-480B-BE2D-6F1494CC3D2FQ38871281-B21FF64A-5F9C-4254-9A08-0DCEF8D79009Q47418815-462F1B25-4A77-4ACB-B31A-AB32E2E796E8Q47585528-C267DC84-9A24-449C-96FA-921DA179376AQ48109577-3B0A019A-606C-43EC-BD1E-43D9F72E840AQ50073064-24AF85C9-80DD-4B25-A986-48627C7D11FEQ50296996-31DA6CC3-8199-424B-BE73-1DC4CF7DC4D3Q52673051-36A8947D-10A6-467E-990F-BE560F08E6FCQ57280000-4FBA3B5C-FBAD-4435-8644-953EFBE09F63Q57803154-A7624B48-3834-4B72-8A6E-DF893C49C47BQ58727126-0A7567D4-99ED-400E-8C62-FCA3B3155FC3Q68097917-C91209A4-9258-42E6-9E6E-2F7B4BD7068AQ68097920-7DDC056B-D386-4304-92D2-386E78592E10Q68097922-96B5AB94-470C-4552-865E-3846E7EED945Q89757652-613E95C5-0EE0-4304-8DA3-65DC6D9D4C0FQ89987480-8078E8F1-7755-4E8E-A2E0-C93ECD45DF91Q89990391-2F94DD0E-E9B1-42D6-9AAA-447B9B9178BDQ90605539-90D74B59-F3E5-4658-B9C4-8D51DBF1F4A2Q90667007-4F82C0F3-72DA-482A-8BDA-D399A83CF639Q90815292-2A3F22A1-2C8B-45EF-95E2-B01A209BA63EQ90831703-BB22BD76-4573-4D25-B229-2DAE9A33E681Q90935093-C327DF41-6791-4DE6-B9B8-394B89B08C80Q91003424-CEA1A6AC-67EF-456A-9E46-7D28EFB85D3CQ91017488-E6965580-EBD0-4B20-9D11-31962E5DA82DQ91269203-94B1E323-935F-4A72-9BFA-626A38E4A9D2Q91304229-03299480-33EF-4B50-8A76-8699E1D52122Q92076321-053E9921-92B4-48FE-B6BB-F2D236B68D50Q93081913-EE849CD6-E816-4F15-AB68-48CE5EC7E052Q95307216-5FE87982-A9D2-4E37-A9FC-2AC6A1C9E42F
P50
description
Pools onderzoekster
@nl
hulumtuese
@sq
researcher
@en
հետազոտող
@hy
name
Dominika Wcisło-Dziadecka
@ast
Dominika Wcisło-Dziadecka
@ca
Dominika Wcisło-Dziadecka
@cs
Dominika Wcisło-Dziadecka
@en
Dominika Wcisło-Dziadecka
@es
Dominika Wcisło-Dziadecka
@gl
Dominika Wcisło-Dziadecka
@hr
Dominika Wcisło-Dziadecka
@hsb
Dominika Wcisło-Dziadecka
@it
Dominika Wcisło-Dziadecka
@nl
type
label
Dominika Wcisło-Dziadecka
@ast
Dominika Wcisło-Dziadecka
@ca
Dominika Wcisło-Dziadecka
@cs
Dominika Wcisło-Dziadecka
@en
Dominika Wcisło-Dziadecka
@es
Dominika Wcisło-Dziadecka
@gl
Dominika Wcisło-Dziadecka
@hr
Dominika Wcisło-Dziadecka
@hsb
Dominika Wcisło-Dziadecka
@it
Dominika Wcisło-Dziadecka
@nl
prefLabel
Dominika Wcisło-Dziadecka
@ast
Dominika Wcisło-Dziadecka
@ca
Dominika Wcisło-Dziadecka
@cs
Dominika Wcisło-Dziadecka
@en
Dominika Wcisło-Dziadecka
@es
Dominika Wcisło-Dziadecka
@gl
Dominika Wcisło-Dziadecka
@hr
Dominika Wcisło-Dziadecka
@hsb
Dominika Wcisło-Dziadecka
@it
Dominika Wcisło-Dziadecka
@nl
P214
P106
P1412
P1559
Dominika Wcisło-Dziadecka
@pl
P21
P214
P27
P31
P496
0000-0003-0501-7592
P735
P7859
viaf-311810870